Form 8-K - Current report:
SEC Accession No. 0001104659-20-023939
Filing Date
2020-02-21
Accepted
2020-02-21 17:00:55
Documents
4
Period of Report
2020-02-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 4.01: Changes in Registrant's Certifying Accountant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm209556d1_8k.htm 8-K 23568
2 EXHIBIT 99.1 tm209556d1_ex99-1.htm EX-99.1 9295
3 GRAPHIC image_002.jpg GRAPHIC 12503
4 GRAPHIC image_003.jpg GRAPHIC 2742
  Complete submission text file 0001104659-20-023939.txt   55681
Mailing Address 700 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 700 TECHNOLOGY DRIVE PITTSBURGH PA 15219 6464501790
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

EIN.: 465622433 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 20640945
SIC: 2834 Pharmaceutical Preparations